EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the ...
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the nextâ€...
As real-world evidence assumes a growing role in oncology research, regulatory evaluation, and clinical decision-making, the quality of underlying data has...
The promise of precision oncology depends not only on scientific innovation but also on successful implementation in routine clinical practice. Drawing on ...
As oncology practices face increasing patient demand and looming workforce shortages, advanced practice providers (APPs) are becoming an essential part of ...
As oncology care becomes increasingly personalized and technology-enabled, digital tools are playing a growing role in improving patient outcomes beyond th...
As oncology care becomes increasingly complex, traditional attribution models used in value-based care programs may no longer fully reflect how patients ar...
Zymo Research, a global leader in genomics tools, announced the launch of Zymo Services, a dedicated portfolio of end-to-end next-generation sequencing (...
As artificial intelligence becomes increasingly embedded in healthcare research, the ability to generate reliable, transparent, and regulatory-grade eviden...
As biotech companies navigate increasingly complex pathways from scientific discovery to commercial success, the importance of location, expertise, and eco...
Mevion Medical Systems has signed a definitive purchase agreement to bring the MEVION S250-FIT Proton Therapy System™ to Tam Anh General Hospital i...
Award funds collaboration with leading Parkinson’s researcher, Dr. Tim Greenamyre, to investigate a novel therapeutic approach for Parkinson&rsqu...
Ebola IC50 (0.125μM)—Strong inhibition at less than half the concentration of the clinically-tested COVID-19 (0.28μM). ...
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study Innovent Biologics, Inc. ("I...
© 2026 Biopharma Boardroom. All Rights Reserved.
